Pan-RAF Inhibitor Scaffold for Broader RAF Mutation Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing B-RAF selective drugs are ineffective as monotherapy for B-RAF V600E mutant colorectal cancers due to the involvement of other RAF family members and require combination therapy, while B-RAF V600E mutant skin cancers are sensitive to these drugs, and atypical B-RAF (non-V600E) tumors show limited clinical benefit.
Innovation Solution
Development of pan-RAF inhibitors, including compounds of formula (I), (I-A), (I-B), (II), (III), and (IV), which target multiple RAF kinases, offering a broader spectrum of activity against RAF family members.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If B-RAF selective drugs are used for B-RAF V600E mutant colorectal cancers, then sensitivity to treatment is achieved in skin cancers, but therapeutic efficacy is lost in colorectal cancers due to involvement of other RAF family members
Solution Approach 1:
The patent applies universality by designing pan-RAF inhibitors that can inhibit multiple RAF kinases (B-RAF, C-RAF, and A-RAF) simultaneously, rather than selecting for B-RAF only. This multi-functional approach allows the inhibitor to address the involvement of other RAF family members in colorectal cancer while maintaining efficacy in B-RAF V600E mutant skin cancers, thus resolving the contradiction between therapeutic efficacy and spectrum of activity.
2Adaptability or versatility
If B-RAF selective therapies are used, then treatment is effective for B-RAF V600E mutant skin cancers, but clinical benefit is limited for atypical B-RAF (non-V600E) and other RAF driven tumors
Solution Approach 1:
The patent employs universality by creating pan-RAF inhibitors with broad activity against all RAF family members including atypical B-RAF (non-V600E) mutants. This ensures clinical benefit across diverse tumor types driven by different RAF mutations, while maintaining reliability through demonstrated efficacy in both skin cancers and colorectal cancers.
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of RAF inhibitors to achieve pan-RAF inhibition rather than selective B-RAF inhibition. This structural modification changes the specificity parameter of the inhibitor, enabling it to target multiple RAF kinases with different mutation profiles, thus expanding applicability to atypical B-RAF and other RAF driven tumors while maintaining clinical benefit.
3Adaptability or versatility
If pan-RAF inhibitors are developed to target multiple RAF kinases, then spectrum of activity is improved, but drug design complexity increases
Solution Approach 1:
The patent addresses drug design complexity by applying universality through a systematic approach: identifying common structural features required for pan-RAF inhibition, optimizing a core molecular scaffold to bind multiple RAF kinases, and iteratively refining the compound based on biochemical and cellular assays. This methodical process manages complexity while achieving broad spectrum of activity against RAF family members.
Data Source
AI summary
The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.